Life sciences company Revvity (NYSE: RVTY) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 7.4% year on year to $709.6 million. The company expects the full year’s revenue to be around $2.86 billion, close to analysts’ estimates. Its non-GAAP profit of $1.37 per share was 5.7% above analysts’ consensus estimates.

Is now the time to buy RVTY? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Revvity’s third quarter was marked by broad-based revenue growth and margin expansion, leading to a positive market reaction. Management credited robust results to improved demand from pharmaceutical and biotechnology customers, particularly in the Life Sciences segment, and highlighted strong execution in both reagents and instruments. CEO Prahlad Singh noted, “Underlying market demand trends from our pharma-biotech customers continued to improve in the third quarter, following the policy-related headwinds our industry faced throughout much of last year.” The quarter also benefited from incremental AI-related demand that began to expand across more areas of the portfolio.

Looking ahead, Revvity’s raised full-year guidance is underpinned by expectations for continued operational efficiency and early-stage AI-driven demand across its product lines. Management sees further momentum in its Signals Software business and ongoing growth in high-content screening, while also investing in capacity to meet prospective increases in demand. CFO Max Krakowiak emphasized that structural improvements in cost management and favorable business mix will support margins, stating, “Our operational efficiency actions are clearly having an impact, and the improved growth in areas such as our life sciences reagents and Signals Software business are favorably impacting our mix.”

Key insights from management’s remarks

Management attributed the quarter’s outperformance to a combination of recovering end-market demand, expanding AI-driven workflows, and new product launches across software and diagnostics.

• Life Sciences momentum: The Life Sciences segment delivered 9% organic growth, with strong performance in reagents and instruments. Management highlighted that improved demand from pharma and biotech customers, alongside academic and government recovery, drove sales momentum across geographies.

• AI-related demand expansion: Incremental demand related to artificial intelligence began extending beyond high-content screening into broader parts of the portfolio. Singh explained that customers are leveraging larger biological datasets to train AI models, fueling demand for both instruments and reagents.

• Signals Software launches: The Signals Software business saw organic growth in the high teens, supported by new product launches including Signals LabGistics, Xynthetica, BioDesign, and integration with Anthropic. Management described this as the most significant year for new product introductions in the division’s history.

• Diagnostics innovation: The Diagnostics segment achieved mid-single-digit growth, buoyed by the European launch of the CE-IVDR-certified GSP T1D 3plex kit for early detection of type 1 diabetes. This test leverages existing infrastructure, opening new markets for early childhood screening.

• Operational efficiency impact: Streamlined operations, such as consolidating R&D and manufacturing in Massachusetts, contributed to margin gains. Adjusted operating margins for Diagnostics exceeded 30% (excluding China), reflecting cost discipline and improved business mix.

Drivers of future performance

Revvity expects continued organic growth and margin expansion, with AI adoption and product innovation seen as key revenue and profitability drivers.

• AI and data-driven demand: Management sees AI adoption as an ongoing catalyst for demand, especially in high-content and high-throughput screening. Singh noted that as customers build larger datasets for AI, Revvity’s instruments and reagents will become increasingly central to experimental workflows.

• Signals Software growth: The company anticipates continued double-digit growth in its Signals Software business, driven by recent launches and strong customer renewals. However, management acknowledged that new product contributions will ramp gradually due to longer sales cycles typical of enterprise software.

• Operational leverage and efficiency: Ongoing operational improvements and a favorable business mix are expected to support operating margins. Krakowiak stated that structural efficiency actions taken over the last 18 months will continue to benefit margins, even as Revvity increases investments to support future growth.

Catalysts in upcoming quarters

Looking ahead, the StockStory team will be monitoring (1) the pace of AI-driven adoption in both instruments and reagents, (2) customer uptake and monetization of Signals Software’s new offerings, and (3) sustained operational efficiency gains in diagnostics and manufacturing. Progress on the divestiture of the China immunodiagnostics business and expansion of partnerships, such as with Genomics England, will also be important to track as indicators of execution and growth potential.

Revvity currently trades at $162.78, up from $151.65 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).

Our favorite stocks right now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.